Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of teclistamab vs PVd or Kd in relapsed/refractory multiple myeloma
2022-000928-37Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of teclistamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-Free Survival. Started Sep 2022; status: active.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2022-000928-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000928-37.